We analysed the frequency of azole and echinocandin resistance in Candida isolates (n " 75) collected between 2012 and 2014 at the University Hospital of Federal University of Juiz de Fora (Brazil). The primary targets erg11 (azoles) and fks1 (echinocandins) were sequenced and modelled at the protein level. Antifungal susceptibility testing was performed according to CLSI (M27-A3 and M27-S4) and according to EUCAST.
Introduction
Candida infections are an important global health problem, resulting in high morbidity and mortality, 1 particularly with drugresistant isolates. 2 At risk are immunocompromised patients and those requiring chemotherapy, antibiotic therapy or long-term catheterization.
2,3 Candida albicans is the major species causing disseminated candidiasis, but other yeasts are on the rise. 4 Worldwide, Candida tropicalis is the third or fourth most common 5, 6 but in Latin America constitutes the second most common yeast. 7 A Brazilian long-term (11 year) epidemiological survey, analysing 388 candidaemia cases, found that 27.3% of the cases were due to C. tropicalis. 8 The first-choice therapy for candidaemia is fluconazole. Long-term fluconazole use triggers the increase of nonalbicans Candida species (NAC) with reduced azole susceptibility. 9 As only three drug classes are available, physicians face the challenges of an increased rate of cross-resistant (substances of different classes), pan-resistant (all substances of one class) or MDR (multiple drugs of different classes) fungi.
In a previous study, 10 the frequency of fluconazole resistance and the relevance of efflux pumps (ABC or MFS transporters) of Candida isolates were investigated. This study aimed to further characterize these isolates by sequencing their primary antifungal target genes fks1 (echinocandins) and erg11 (azoles).
Methods
Seventy-five Candida isolates were mainly obtained from different clinical materials (urine, faeces, catheters, blood and other secretions) between 2012 and 2014 from ICU patients and ambulant patients (Table S1 , available as Supplementary data at JAC Online). Isolates were grown on Sabouraud dextrose agar (SDA) for 24 h at 37 C and identified using MALDI Microflex LT (Bruker Daltonics, Bremen, Germany), as previously described.
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Antifungal susceptibility testing of itraconazole and fluconazole (Sigma-Aldrich, St Louis, MO, USA), voriconazole and anidulafungin (Pfizer Pharma), posaconazole and caspofungin (Merck) and micafungin (Astellas) was performed according to CLSI document M27-A3 12 and interpreted following M27-S4; 13 in addition, strains were tested according to EUCAST.
14 Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were used as quality control. Clinical breakpoints for Candida spp. were used to interpret MIC data per method. Per species, drug and method, MIC range, MIC 50 and MIC 90 were calculated. DNA extraction and purification were performed as previously described 15 from overnight cultures. Hot spot region 1 (HS1) (amino acid positions 641-649) and hot spot region 2 (HS2) (amino acid positions 1357-1364) of lanosterol 14-a-demethylase (erg11) 16, 17 and 1,3-b-glucan synthase (fks1) genes were amplified and sequenced using the primers given in Table S2 . The PCR conditions for erg11 were: 95 C/4 min, followed by 45 cycles of 95 C/10 s, annealing temperature (Table S2) /60 s and 72 C/90 s (except C. albicans 150 s), followed by 72 C/5 min. For fks1, PCR conditions were according to Lackner et al. 17 SNP analyses were performed as previously described 18 and translations and amino acid sequence alignments were made with Geneious software v. 8.1.6.
Point mutations found in erg11 were studied in a homology model constructed with SWISS-MODEL platform (http://swissmodel.expasy.org). The crystal structure of Saccharomyces cerevisiae erg11 (with intact transmembrane domain bound to itraconazole), 19 deposited in the Protein Data Bank (http://www.rcsb.org) with code 5EQB, was used as template to generate a three-dimensional homology model for C. tropicalis, C. albicans and Candida kefyr. Both global and per-residue model quality were assessed using the QMEAN scoring function. 20 Results and discussion C. albicans was the most frequent yeast (38.6%) followed by C. tropicalis (30.6%); for the numbers/percentages of other yeasts and their isolation sites see Table S1 . In general, C. tropicalis is intrinsically susceptible to azoles and echinocandins. 21 MICs for Candida isolates generated by EUCAST tended to be 1-to 2-fold dilutions higher than those with CLSI (Table 1 and Table S3 ); high variations were observed for voriconazole and posaconazole (Figure 1b and c).
Using EUCAST clinical break points (CBPs), more C. tropicalis strains were categorized as azole resistant than by CLSI CBPs (Table 1) . MIC distributions (EUCAST and CLSI) of azoles and for C. tropicalis are illustrated in Figure 1 . In our study, 50% of C. tropicalis isolates were resistant to one or multiple azoles, and six C. tropicalis isolates were pan-azole resistant and echinocandin susceptible (Table 1) . Echinocandin-resistant C. tropicalis has been reported in the USA and found to be associated with a history of echinocandin therapy. 22, 23 Worldwide the number of fluconazole-resistant C. tropicalis is on the rise: an increase of 70.0% was observed in Denmark 24 and an increase of 40.0% in Japan. 25 Also, cross-resistance (fluconazole-triazoles) occurs in C. tropicalis with a frequency of 4.5%. 22 In short, the majority (i.e. apart from two isolates that were itraconazole or voriconazole resistant) of C. albicans isolates were azole and echinocandin susceptible (Table S3) , which is in agreement with a previous study. 26 In contrast, 10 Candida glabrata isolates were categorized as azole resistant based on ecological cut off values (ECOFFs) shown in Table S4 . One C. glabrata strain (218i) was pan-azole and caspofungin resistant; the emergence of such multiresistant C. glabrata strains was has been described previously. 27 Most C. glabrata isolates were resistant to caspofungin, while resistance to anidulafungin was rare and absent for micafungin (Table S4) . C. parapsilosis isolates were resistant to itraconazole and posaconazole (Table  S4) . One MDR C. parapsilosis strain (strain 177i), resistant to micafungin, itraconazole, posaconazole and fluconazole, was found (Table S4 ), which is rare. 28 Candida metapsilosis and C. krusei were susceptible to all drugs. One C. kefyr isolate was cross-resistant (posaconazole and fluconazole) (Table S5) . The possible involvement of ABC transporters in the resistance profile of these C. tropicalis isolates was observed in a previous work by Neves-Junior et al. 10 These isolates were chemosensitized with FK506 (tacrolimus), a classic inhibitor of Candida ABC transporters, 35 that was able to revert the resistance phenotype. Emergence of pan-azole resistance in Candida tropicalis
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The essential agreements (EAs) between EUCAST and CLSI per drug and species are given in Table S6 . In short, EAs for C. albicans were 96.6% for echinocandins and azoles (with the exception of posaconazole, 86.2%) and overall agreement for all drugs was 96.6%. For C. glabrata EA was 100.0% for all echinocandins and 92.3% for itraconazole; all other drugs had EAs .80%. Low-level EAs were found for C. parapsilosis and C. tropicalis and azoles, but EAs for echinocandins were high (100.0%).
erg11 and/or fks1 amino acids were compared between resistant and susceptible isolates. No coding mutations were found for drug-resistant C. glabrata and C. parapsilosis (Tables S7 and S8) . A cross-resistant (posaconazole and fluconazole) C. kefyr ("Kluyveromyces marxianus; strain 124A) isolate carried the erg11 amino acid substitution K189R (Table S7 ). The homology model of the erg11p was built on the basis of K. marxianus TEM and compared with 124A. Our analysis revealed that K189R is very unlikely to be the cause of azole resistance ( Figure S1 ). Azole-resistant C. albicans isolates (217i and 541i) carried missense mutations in the erg11 gene; 217i carried the amino acids D116E, T220L and K128T, and 541i carried D116E and T220L (Table S7 ). The erg11 HS1 Xisto et al.
mutations D116E and K128L have been described previously ( Figure S2) . 29 These amino acid changes are unlikely to confer any azole resistance. The only C. krusei isolate found in this study carried one missense mutation in the fks1 HS1 region, namely L701M (Table S7 ). This amino acid substitution has been previously reported in a strain with elevated caspofungin MIC, 30 although it is located outside of the HS1 region and its relation with any resistance mechanism is uncertain. In C. tropicalis (24i and 403i; Table 1 ) two isolates were homozygous for the K143R amino acid substitution in erg11. K143R was previously associated with fluconazole resistance in clinical C. albicans isolates. [31] [32] [33] Mutations at K143 may interfere with the entry of the inhibitor/substrate or its binding to the active site. Moreover, Chau et al. 31 showed that the expression of either K143R or K143X from C. albicans in an S. cerevisiae mutant led to an increase in fluconazole, voriconazole and itraconazole MICs. In a more recent work, 34 the mutation K143R was introduced homozygously in the azole-susceptible C. albicans reference strain SC5314, resulting in the strongest decrease in fluconazole susceptibility yet observed; however, voriconazole was only moderately affected. When K143R was combined with the alteration Y132F, strains showed a 32-fold and 4-fold increase in fluconazole and voriconazole MICs, respectively. 34 C. tropicalis WT strain (ATCC 750) and the isolates (24i and 403i) carrying the amino acid change K143R in HS1 were evaluated within the homology protein model ( Figure S3 ). Neighbouring residues (tyrosine 132 and serine 154) in the active site of the erg11p of C. tropicalis 31 were chosen for the measurements of polar interactions, alterations and distances ( Figure S3b ). Polar contacts (4.4-6.0 Å ) between K143R and itraconazole are shown in Figure S3 (c). The mutation K143R maps near the active binding site and therefore is very likely to confer high fluconazole and triazole resistance to C. tropicalis. Both strains (24i and 403i) exhibiting the amino acid change K143R have altered MICs of all azoles. In addition to the mutation K143R in erg11, ABC transporters were also up-regulated, which may contribute to the highly resistant pan-azole-resistant phenotype of these strains (Table 1 ).
Conclusions
Our data suggest an emergence of azole-and echinocandinresistant Candida isolates in Brazilian patients. The highest frequencies of triazole resistance, pan-azole resistance and multidrug resistance were found in C. tropicalis and C. glabrata. In the erg11 of pan-azole-resistant C. tropicalis strains, the point mutation K143R was found together with an up-regulation of ABC transporters. According to our protein homology model and previously published data by Chau et al., 31 it is very likely that the mutation K143R causes pan-azole resistance. In vivo outcome studies and comprehensive epidemiological studies are needed to evaluate whether pan-azole-resistant C. tropicalis strains carrying the mutation K143R are on the rise in Latin America. 
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